Secondary Malignant Neoplasm of Liver
12
1
1
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
2 terminated out of 12 trials
71.4%
-15.1% vs benchmark
8%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
A Trial on SBRT Versus MWA for Inoperable Colorectal Liver Metastases (CLM)
Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer
Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis
Computertomography-guided Wire Marking of the Liver
Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)
Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery
Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence
Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only